Rho Inhibitor II, Y16 (PDZ Rho-Binding Domain Blocker, LARG Rho-Binding Domain Blocker, (E)-4-(3-(3-Methylbenzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (4E)-4-(3-(3-Methylbenzyloxy)benzylidene)-1-phenyl-3,5-pyrazolidinedione, p115 Rho-Binding Domain Blocker)

Größe

£409.00

SKU:: 217743
Molekulargewicht:: 384.4
Reinheit:: ≥95% (HPLC)
Lagerbedingungen:: 4°C
Hersteller:: United States Biological
Format:: Supplied as an orange powder.
Weitere Details:: A cell-permeable pyrazolidinedione compound that is shown to target RhoGEF DH-PH domain junction with high affinity (Kd = 65nM) and effetively prevent RhoGEFs LARG, p115, and PDZ from interacting with RhoA, while displaying little potency against DBL-RhoA, LBC-RhoA, intersectin-Cdc42, or TrioN-Cdc42 interaction. Shown to completely prevent serum-induced activation of cellular RhoA, but not Cdc42 or Rac1, in NIH-3T3 cultures (10uM) and RhoA downstream signaling events. Greatly synergizes with Rho GEF-binding domain blocker Rhosin in blocking RhoA-LARG interaction and in preventing cellular RhoA activation (both drug at 5uM). Synonyms: LARG Rho-Binding Domain Blocker, (E)-4-(3-(3-Methylbenzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (4E)-4-(3-(3-Methylbenzyloxy)benzylidene)-1-phenyl-3,5-pyrazolidinedione, p115 Rho-Binding Domain Blocker, PDZ Rho-Binding Domain Blocker Molecular Formula: C₂₄H₂₀N₂O₃ Primary Target: RhoGEF Molar Mass: 384.4 Solubility: DMSO Storage and Stability: Store at 4°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.